Last reviewed · How we verify
Skin and Skin Structure Streptococcus Agalactiae Infection
Approved treatments
- Zithromax · Pfizer Inc.
Macrolide antibiotic that binds the 50S ribosomal subunit, inhibiting bacterial protein synthesis with an exceptionally long tissue half-life. - Monocid
- Teflaro · AbbVie
Teflaro works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death. - Cefotan
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Skin and Skin Structure Streptococcus Agalactiae Infection patent landscape — cliff calendar, originator estates, attackable patents
- Skin and Skin Structure Streptococcus Agalactiae Infection treatment landscape brief
- Skin and Skin Structure Streptococcus Agalactiae Infection treatment updates RSS
Frequently asked questions about Skin and Skin Structure Streptococcus Agalactiae Infection
What drugs treat Skin and Skin Structure Streptococcus Agalactiae Infection?
Tracked treatments include Zithromax, Monocid, Teflaro, Cefotan.
What is the treatment for Skin and Skin Structure Streptococcus Agalactiae Infection?
Standard treatment for Skin and Skin Structure Streptococcus Agalactiae Infection includes Zithromax, Monocid, Teflaro, Cefotan. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Skin and Skin Structure Streptococcus Agalactiae Infection patent cliff · Skin and Skin Structure Streptococcus Agalactiae Infection CI report
- Treatment: Zithromax · Pfizer Inc.
- Treatment: Monocid
- Treatment: Teflaro · AbbVie
- Treatment: Cefotan
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing